Lv8
8130 积分 2020-10-11 加入
A 3D morphogenetic blueprint for metastatic outgrowth in breast cancer
10天前
已完结
Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial
1个月前
已完结
Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial
1个月前
已完结
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
2个月前
已完结
Lessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the EMERALD Study
3个月前
已关闭
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
3个月前
已完结
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
4个月前
已完结
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial
5个月前
已完结
[Breast cancer treatment guidelines(2022 edition)]
8个月前
已完结
Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer
8个月前
已完结
皖公网安备34019202002308
